GSM gold starGSM Global
中文版 · Chinese

Apramycin in Dextran Nanoparticles Shows No Significant Difference From Free Drug Against 11 Acinetobacter baumannii Isolates In Vitro

Monday, November 16, 2026 · Technology · GSM News

Researchers at the Biogipuzkoa Health Research Institute, CIDETEC and the University of the Basque Country in Spain published a paper in Scientific Reports on 15 November: apramycin formulated with dextran-based single-chain polymeric nanoparticles showed, overall, no significant difference from the free drug in in vitro antimicrobial activity against eleven Acinetobacter baumannii clinical isolates.

The team formulated a series of nanoparticles with different physicochemical properties, namely three degrees of substitution, low, medium or high, and two degrees of crosslinking at a medium degree of substitution, low or high. Their in vitro activity against eleven Acinetobacter baumannii clinical isolates was assessed compared with the free drug, using minimum inhibitory concentration, minimum bactericidal concentration and time-kill kinetic assays.

Overall, no statistically significant differences were observed between the antimicrobial activity of free and formulated apramycin. Nevertheless, a slight trend towards higher activity was observed in the cases of the medium-substitution and high-crosslinking formulations.

The authors said the global emergence of antimicrobial resistance is driving the development of novel strategies for treating bacterial infections, and that dextran-based single-chain polymeric nanoparticles have been developed as antibiotic delivery systems for the treatment of pulmonary infections. The study reports in vitro results.

Source: Scientific

Published by GSM · USA (original Chinese edition)

Photo: 图中是扫描电子显微镜下的鲍曼不动杆菌,本研究测试的细菌。来源:Wikimedia Commons,Vader1941,CC BY-SA

Latest in Technology